Covid: 'Covaxin neutralises Delta & Alpha variants'
In yet another booster shot of endorsement for India’s Covaxin, the US’ National Institutes of Health has said that the vaccine is able to effectively neutralise the Alpha and Delta variants of SARS-CoV-2. Citing Phase 2 trial published in The Lancet, NIH said the results indicate that Covaxin is “safe and well-tolerated” and that Phase-3 trial indicate it has 78% efficacy.
admin 
In yet another booster shot of endorsement for India’s Covaxin, the US’ National Institutes of Health has said that the vaccine is able to effectively neutralise the Alpha and Delta variants of SARS-CoV-2. Citing Phase 2 trial published in The Lancet, NIH said the results indicate that Covaxin is “safe and well-tolerated” and that Phase-3 trial indicate it has 78% efficacy.
